Skip to main content
AIM Vaccine Co., Ltd. logo

AIM Vaccine Co., Ltd. — Investor Relations & Filings

Ticker · 6660 HKEX Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2025-08-27 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 6660

About AIM Vaccine Co., Ltd.

https://www.aimbio.com

AIM Vaccine Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines for human use. The company's mission is to produce high-quality vaccines to safeguard global health. It holds a leading position among privately-owned vaccine enterprises in its primary market. The core product portfolio includes established vaccines such as Recombinant Hepatitis B Vaccine (Hansenula polymorpha), Inactivated Hepatitis A Vaccine (Human Diploid Cell), and Meningococcal Polysaccharide Vaccine. AIM Vaccine is also a major global supplier of rabies vaccines, committed to leading technological advancements in this area. The company actively expands its pipeline, which features advanced candidates like the 13-valent pneumonia conjugate vaccine and iterative serum-free rabies vaccine, alongside strategic investments in mRNA technology, including an mRNA COVID-19 vaccine candidate.

Recent filings

Filing Released Lang Actions
2025 INTERIM REPORT
Interim / Quarterly Report Classification · 1% confidence The document is titled '2025 Interim Report' for AIM Vaccine Co., Ltd. It contains comprehensive financial information, including an 'Interim Condensed Consolidated Statement of Profit or Loss', 'Management Discussion and Analysis', and detailed notes to the financial information for the six-month period ended June 30, 2025. It is a full interim financial report, not an announcement or a summary. H1 2025
2025-08-27 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 1% confidence The document is an 'INTERIM RESULTS ANNOUNCEMENT' for AIM Vaccine Co., Ltd. for the six months ended June 30, 2025. It contains comprehensive unaudited interim condensed consolidated financial statements, including the statement of profit or loss, statement of financial position, statement of changes in equity, and statement of cash flows, along with detailed notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H2 2025
2025-08-27 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a short HKEX announcement notifying shareholders of an upcoming Board meeting to approve interim results. It does not provide the interim report itself, nor does it announce management changes, dividends, or financing actions. There is no proxy solicitation or detailed report attached—just a notice of the board meeting. Since there is no specific category for “Notice of Board Meeting,” it falls under the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as Regulatory Filings (RNS).
2025-08-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025
Share Issue/Capital Change Classification · 1% confidence The document is a statutory Monthly Return (Form FF301) filed with the Hong Kong Exchange detailing movements in authorised/registered share capital and issued shares under Chapter 19B of the Listing Rules. It focuses exclusively on monthly changes (or, in this case, confirmations of no change) to share capital and issued share figures. This aligns with the “Share Issue/Capital Change” category, which covers announcements regarding changes (or summaries thereof) in authorised and issued share capital.
2025-08-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
Regulatory Filings Classification · 1% confidence The document is an HKEX ‘Monthly Return for Equity Issuer and Hong Kong Depositary Receipts’ (Form FF301) detailing monthly movements in share capital and issued shares under the Exchange Listing Rules. It is not an Annual Report (10-K), Interim Report (IR), earnings release (ER), or any other financial report category; nor does it announce a specific capital transaction (SHA). It is a routine regulatory filing required by the exchange. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2025-07-02 English
CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT
Board/Management Information Classification · 1% confidence The document is an official announcement by the Board of AIM Vaccine Co., Ltd. disclosing the resignation and appointment of joint company secretaries and authorised representatives. It relates to changes in senior corporate officers (company secretaries) rather than financial results, dividends, M&A, or other topics. This fits the definition of Board/Management Information (MANG).
2025-06-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.